Raymond James Financial
ENGN icon

Raymond James Financial’s enGene Therapeutics ENGN Stock Holding History

Raymond James Financial’s Portfolio ENGN Stock Details ENGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$143K Buy
20,999
+1,039
+5% +$9.25K ﹤0.01% 4956
2025
Q4 		$180K Buy
19,960
+9,960
+100% +$79.8K ﹤0.01% 4816
2025
Q3 		$68.3K Buy
10,000
+7,932
+384% +$36.2K ﹤0.01% 4792
2025
Q2 		$7.53K Buy
+2,068
New +$7.76K ﹤0.01% 6039

Other funds holding ENGN

FIS
FCPM III Services Naarden, Netherlands $722M AUM 73.61% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return
VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return
BOCH
Blue Owl Capital Holdings New York $372M AUM 78.25% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
B
Braidwell Stamford, Connecticut $3B AUM 46.72% 1-Year Est. Return
NI
Nextech Invest Zurich, Switzerland $1.42B AUM 304.47% 1-Year Est. Return
VPC
Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return
MB
MPM BioImpact Boston, Massachusetts $1.29B AUM 141.72% 1-Year Est. Return

Raymond James Financial's ENGN Position: Q1 2026 in Review

Raymond James Financial increased its enGene Therapeutics (ENGN) stake by 5.2% in Q1 2026, buying an estimated $9.25K and bringing the position to 20,999 shares worth $143K. The position accounts for ﹤0.01% of the portfolio, ranked #4956.

Raymond James Financial first reported a position in ENGN in Q2 2025 and has held it in 4 quarters since. The position peaked at $180K in Q4 2025. 61 funds tracked by Wall St. Rank hold ENGN as of Q1 2026.

  • Raymond James Financial held 20,999 shares of enGene Therapeutics worth $143K as of Q1 2026.
  • Raymond James Financial bought 1,039 enGene Therapeutics shares in Q1 2026, an estimated $9.25K.
  • enGene Therapeutics made up ﹤0.01% of Raymond James Financial's portfolio in Q1 2026, its #4956 holding.
  • Raymond James Financial first reported a position in enGene Therapeutics in Q2 2025 and has held it in 4 quarters since.
  • Raymond James Financial's enGene Therapeutics position peaked at $180K in Q4 2025.
  • 61 funds tracked by Wall St. Rank held enGene Therapeutics as of Q1 2026.

Based on Raymond James Financial's 13F filing for Q1 2026, filed 14 May 2026.